Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the Kinetics of Antibodies Against SARS-CoV-2 and of Cellular Subpopulations of the Immune System in Volunteers Receiving the BNT162b2 Vaccine or Other Approved Vaccine Against SARS-CoV-2

Next Previous
Trial Profile

Study of the Kinetics of Antibodies Against SARS-CoV-2 and of Cellular Subpopulations of the Immune System in Volunteers Receiving the BNT162b2 Vaccine or Other Approved Vaccine Against SARS-CoV-2

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 1222 (Primary) ; Tozinameran (Primary) ; COVID-19 vaccines
  • Indications COVID 2019 infections
  • Focus Pharmacodynamics

Most Recent Events

  • 13 Dec 2022 Results (n=80) reporting anti-SARS-CoV-2 humoral immune responses data from five patients cohorts presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 08 Apr 2022 Planned End Date changed from 1 Apr 2022 to 1 Dec 2022.
  • 08 Apr 2022 Planned primary completion date changed from 1 Nov 2021 to 1 Aug 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top